BMRN Q3 2022 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$505M+23.6% YoY

Gross Profit

$389M77.0% margin

Operating Income

-$2M-0.5% margin

Net Income

-$7M-1.3% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-5.3%

Cash Flow

Operating Cash Flow

$158M

Free Cash Flow

$122M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$6.3B

Total Liabilities

$1.7B

Stockholders' Equity

$4.6B

Cash & Equivalents

$762M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$505M	$409M	+23.6%
Gross Profit	$389M	$305M	+27.5%
Operating Income	-$2M	-$53M	+95.5%
Net Income	-$7M	-$36M	+81.8%

Revenue Segments

Product

$493M98%

Royalty And Other

$12M2%